IRCT20190706044111N10Not yet recruiting未知
A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Dexamethasone 4mg tablet of Abureihan Pharm Co., IRAN in comparison of Dexamethasone 4mg tablet of GALEN in 24 healthy adult subjects under fasting condition
Aburaihan Pharm Co.0 sites24 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 50 years (—)
- Sex
- All
Inclusion Criteria
- •Aged between 20 - 50 years
- •Body weight between 50 – 100 kg
- •Having good health on the basis of medical history and physical & clinical examination
- •Understand the procedures and give written informed consent.
Exclusion Criteria
- •Subject showed clinically relevant deviations from normal in physical examination.
- •Subject had undergone surgery of the gastro-intestinal tract
- •Subject had donated a unit of blood or participated in another clinical trial, within the last 8 weeks before the first treatment.
- •Subject had a history of drug or alcohol abuse.
- •Subject who smokes more than 10 cigarettes per day.
- •Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Bioequivalence study of Gabapentin 300mg capsule of Alborzdarou Pharm Co.,euralgia and neuropathic disorders.IRCT20190706044111N6Alborzdarou Pharm. Co.24
Completed
Not Applicable
Bioequivalence study of Rosuvastatin 20 mg tablet of Aburaihan Pharm Co., IRAHyperlipidemia.IRCT20190706044111N9Aburaihan Pharm Co.24
Completed
Not Applicable
Bioequivalence study of Aristatin 10mg tablet of Arya Pharm Co., IRAHyperlipidemia.IRCT20190706044111N8Arya Pharm Company24
Not yet recruiting
Unknown
Bioequivalence study of Famotidine 40mg tablet of Amin Pharm Co., IRAstomach ulcers.histamine H2-receptor blockersT47. 0X3IRCT20190706044111N36Amin Pharm. Co.24
Recruiting
Not Applicable
Bioequivalence study of Aristatin 20mg tablet of Arya Pharm Co., IRAIRCT20190706044111N7Arya Pharm Company24